Kombine Hiperlipidemili Hastalarda Tekbaşına Fluvastatin Tedavisi
Küçük Resim Yok
Tarih
2000
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
AMAÇ: Lipit metabolizma bozukluklarından biri olan kombine hiperlipidemi koroner arter hastalığını arttıran önemli bir risk faktörüdür. Çalışmamızda 3-hidroksi-3 metilglutaril koenzim A redüktaz inhibitörlerinden olan Fluvastatin'in kombine hiperlipidemili hastalarda monoterapi olarak etkinliğini ve güvenilirliğini araştırmayı amaçladık. GEREÇ ve YÖNTEM: Kombine hiperlipidemi tespit edilen 83 hasta çalışmaya alındı. Birinci grupdaki 44 olguya diyet 40mg/gün fluvastatin, ikinci grupdaki 35 olguya diyet 80mg/gün fluvastatin ve üçüncü grupdaki 16 olguya ise diyet uygulandı. 28 hafta (4 hafta diyet24 hafta ilaç) süren çalışma sırasında 6 hafta arayla, klinik ve laboratuar olarak 4 kontrol gerçekleştirildi. BULGULAR: Diyet grubu ile karşılaştırıldığında 40 mg ve 80 mg fluvastatin grubunda düşük dansiteli lipoprotein kolesterol (LDL-K) ve trigliserid (TG) düzeylerinin anlamlı olarak düştüğü saptanmıştır (40 mg grubunda sırasıyla p0.001 ve p0.01, 80 mg grubunda sırasıyla p0.0001 ve p0.000l). 40mg grubundan farklı olarak 80mg grubunda apolipoprotein B düzeylerinde anlamlı bir düşme (p0.000l) ve yüksek dansiteli lipoprotein kolesterol (HDL-K) düzeylerinde de anlamlı bir artma (p0.01) saptanmıştır. TG/LDL-K oranı 80 mg/gün grubunda diyet grubuna göre anlamlı olarak yüksekti (p0.05). SONUÇ: Fluvastatin kombine hiperlipidemili hastalarda TG, LDL-K, ve apolipoprotein B konsantrasyonlarını düşürmüştür. HDL-K düzeylerinde ise diyetin ve egzersizin ilaç tedavisi kadar önemli olduğu gözükmektedir.
AIM: Combined hyperlipidemia is one of the risk factors for coronary heart disease. We aimed that as a monotherapy, the effectiveness and safety of fluvastatin, which is HMG-CoA reductase inhibitor, on combined hyperlipidemia. METERIAL AND METHODS: Eighty-nine patients with combined hyperlipidemia were enrolled in this study. Forty-four patients in first group received diet plus fluvastatin 40mg/day, thirty-five patients in second group received diet plus fluvastatin 80 mg/day and sixteen patients in third group received diet therapy. Patients were followed up for a duration of 28 weeks. During follow up, all clinical comprehensive laboratory assessments were repeated for every 6 weeks. RESULTS: After 24 weeks of treatment the mean percent change from baseline was statistically significant for low density lipoprotein cholesterol ( %-32,l; p<0,001 in 40 mg/day , %-4,08; p<0,0001 in 80 mg/day), trygliceride (%-34,6; p<0,01 in 40 mg/day, %-46,5, p<0,0001 in 80 mg/day), apolipoprotein B (%-37,6; p<0,0001 in 80 mg/day) and high-density lipoprotein cholesterol (%14,3; p<0,01 in 80 mg/day). The ratio of triglyceride/low density lipoprotein cholesterol was significantly higher in 80 mg/day group than diet group (1,14; p<0.05). CONCLUSION: Fluvastatin decreased the triglyceride, low density lipoprotein cholesterol and apolipoprotein B levels in serum. The diet and exercise therapies on high-density lipoprotein cholesterol level were found to be effective as well as the drug therapies.
AIM: Combined hyperlipidemia is one of the risk factors for coronary heart disease. We aimed that as a monotherapy, the effectiveness and safety of fluvastatin, which is HMG-CoA reductase inhibitor, on combined hyperlipidemia. METERIAL AND METHODS: Eighty-nine patients with combined hyperlipidemia were enrolled in this study. Forty-four patients in first group received diet plus fluvastatin 40mg/day, thirty-five patients in second group received diet plus fluvastatin 80 mg/day and sixteen patients in third group received diet therapy. Patients were followed up for a duration of 28 weeks. During follow up, all clinical comprehensive laboratory assessments were repeated for every 6 weeks. RESULTS: After 24 weeks of treatment the mean percent change from baseline was statistically significant for low density lipoprotein cholesterol ( %-32,l; p<0,001 in 40 mg/day , %-4,08; p<0,0001 in 80 mg/day), trygliceride (%-34,6; p<0,01 in 40 mg/day, %-46,5, p<0,0001 in 80 mg/day), apolipoprotein B (%-37,6; p<0,0001 in 80 mg/day) and high-density lipoprotein cholesterol (%14,3; p<0,01 in 80 mg/day). The ratio of triglyceride/low density lipoprotein cholesterol was significantly higher in 80 mg/day group than diet group (1,14; p<0.05). CONCLUSION: Fluvastatin decreased the triglyceride, low density lipoprotein cholesterol and apolipoprotein B levels in serum. The diet and exercise therapies on high-density lipoprotein cholesterol level were found to be effective as well as the drug therapies.
Açıklama
Anahtar Kelimeler
Kalp ve Kalp Damar Sistemi
Kaynak
MN Kardiyoloji
WoS Q Değeri
Scopus Q Değeri
Cilt
7
Sayı
6
Künye
Yazıcı, M., Gürbilek, M., Temizhan, A., Telli, H. H., (2000). Kombine Hiperlipidemili Hastalarda Tekbaşına Fluvastatin Tedavisi. MN Kardiyoloji, 7(6), 446-450.
